Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Net Loss per Common Share

Net Loss per Common Share

12 Months Ended

Dec. 31, 2022

13. Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period.

The following shares of potentially dilutive securities, weighted during the years ended December 31, 2022 and 2021 have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be anti-dilutive:



	Year Ended December 31,
	2022	2021
Warrants to purchase Common Stock	3,495,870	4,528,196
Options to purchase Common Stock	724,757	832,134
Unvested Restricted Stock	18,375,001	16,363,068
Unvested Restricted Stock Units	39,125	180,848
Total	22,634,754	21,904,246